Boehringer Ingelheim, an animal health care services provider, agreed to acquire T3 Pharmaceuticals, a clinical stage biotech company, for $509m. “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs. This will bring us closer to achieving our vision of driving a paradigm shift in cancer care treatments,” Michel Pairet, Boehringer Ingelheim Member of the Board of Managing Directors.